Renaissance Technologies LLC reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA – Free Report) by 17.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,262,634 shares of the biotechnology company’s stock after selling 269,987 shares during the period. Renaissance Technologies LLC’s holdings in ADMA Biologics were worth $11,376,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp raised its stake in ADMA Biologics by 0.3% during the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after buying an additional 35,614 shares during the period. Sachem Head Capital Management LP grew its stake in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock valued at $207,480,000 after acquiring an additional 2,415,000 shares during the period. Westfield Capital Management Co. LP grew its stake in ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the period. Capital Research Global Investors raised its position in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the period. Finally, Nuveen LLC lifted its holdings in shares of ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after purchasing an additional 202,245 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.
Key Headlines Impacting ADMA Biologics
Here are the key news stories impacting ADMA Biologics this week:
- Negative Sentiment: The lawsuit alleges that ADMA and certain senior executives made materially misleading statements about the company’s financial condition, revenue recognition, inventory distribution and business practices. The allegations have not been proven in court. Hagens Berman ADMA class action notice
- Negative Sentiment: Additional notices cite more specific claims, including alleged channel stuffing and an undisclosed related-party distributor operating from ADMA’s headquarters. If substantiated, such claims could undermine confidence in reported sales quality and corporate governance. SueWallSt ADMA shareholder alert
- Neutral Sentiment: The reported class period runs from August 9, 2024, through March 25, 2026. Investors who acquired ADMA securities during that period have until August 10, 2026 to apply to serve as lead plaintiff; the deadline is a procedural step and does not determine the merits of the case. Kahn Swick and Foti deadline notice
- Negative Sentiment: Multiple firms—including Lowey Dannenberg, Faruqi & Faruqi, Robbins Geller, Rosen and others—are soliciting affected investors or investigating potential federal securities-law violations. The volume of notices may amplify reputational concerns and litigation overhang even though most releases repeat the same underlying allegations. Lowey Dannenberg ADMA investigation
ADMA Biologics Stock Performance
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. During the same period in the previous year, the company earned $0.11 earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. Equities research analysts forecast that ADMA Biologics Inc will post 0.8 EPS for the current fiscal year.
Insider Buying and Selling at ADMA Biologics
In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director directly owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of brokerages have commented on ADMA. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target for the company. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Mizuho dropped their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.
Read Our Latest Report on ADMA
ADMA Biologics Company Profile
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Read More
- Five stocks we like better than ADMA Biologics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA – Free Report).
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
